Abstract

23
Background 24
Patients with schizophrenia make more errors than healthy subjects on the 25 antisaccade task. In this paradigm, participants are required to inhibit a reflexive 26 saccade to a target and to select the correct action (a saccade in the opposite 27 direction). While the precise origin of this deficit is not clear, it has been 28 connected to aberrant dopaminergic and cholinergic neuromodulation. 29
Methods 30
To study the impact of dopamine and acetylcholine on inhibitory control and 31 action selection, we administered two selective drugs (levodopa 32 200mg/galantamine 8mg) to healthy volunteers (N=100) performing the 33 antisaccade task. A computational model (SERIA) was employed to separate the 34 contribution of inhibitory control and action selection to empirical reaction times 35 and error rates. 36
Results
37
Modeling suggested that levodopa improved action selection (at the cost of 38 increased reaction times) but did not have a significant effect on inhibitory 39 control. By contrast, according to our model, galantamine affected inhibitory 40 control in a dose dependent fashion, reducing inhibition failures at low doses and 41 increasing them at higher levels. These effects were sufficiently specific that the 42 computational analysis allowed for identifying the drug administered to an 43 individual with 70% accuracy. 44
Conclusions 45
Introduction
53
Schizophrenia is a heterogeneous clinical entity: patients with comparable 54 symptoms show highly variable treatment responses and clinical trajectories over 55 time (1; 2) . A key challenge is to devise procedures for differential diagnostics 56 that disambiguate potential disease mechanisms and inform individualized 57 treatment (3). One proposal derives from the "dysconnection hypothesis" which 58 posits that the schizophrenia spectrum consists of different abnormalities in 59 dopaminergic and cholinergic modulation of NMDA receptor dependent 60 plasticity (4-6). This suggests the development of assays of neuromodulation that 61 can operate on individualized clinical data. 62
Eye movements are attractive targets in this regard (7). They (i) can be easily 63 measured in clinical settings, (ii) are sensitive to changes in neuromodulation, 64 and (iii) display abnormalities in schizophrenia. Saliently, it has been 65 consistently reported that patients with schizophrenia make more errors than 66 control participants in the antisaccade task (8-11). In this paradigm, subjects are 67 required to saccade in the opposite direction of a visual cue. This is assumed to 68 probe participants' ability to inhibit a reflexive (pro)saccade towards the cue and 69 to select and initiate the correct action, i.e., an (anti)saccade in the opposite 70 direction (8). However, it remains unclear whether the elevated error rate (ER) 71 in schizophrenia is caused by deficits in inhibitory control of reflexive 72 prosaccades, in selecting correct actions (antisaccades), or by a combination of 73 these factors. 74
All of these options are thought to be related to abnormal neuromodulation. 75
Specifically, aberrant tonic dopamine (DA) levels in the basal ganglia (BG) could 76 lead to abnormalities in the 'NO GO' pathway responsible for the inhibition of 77 reflexive saccades (9) (10) (11) (12) Testing started 70 minutes after drug administration. This delay was chosen to 146 allowed both compounds to reach peak plasma levels (Madopar: 0.7h (49), 147
Reminyl: 0.8-2h (50)). Furthermore, the half-life of levodopa is close to 1.5h 148 (49), whereas galantamine's half-life is 5.2h (50), and thus much longer than the 149 mean duration of the experiment (30min). 150
Task design 151 The main experiment consisted of three blocks of 192 trials. Every block 155 contained randomly interleaved pro-and antisaccade trials, of which 20, 50 or 156 80% were prosaccade trials (conditions PP20, PP50, PP80 respectively). The 157 order of the blocks was identical in both sessions, but pseudo-randomized across 158 subjects. 159
Modeling 160
The first main goal of this study was to quantify the effects of levodopa and 161 galantamine on inhibitory control and action selection. The key observation here 162 is that to complete an antisaccade, two things need to happen. First, a reflexive 163 saccade to the peripheral cue must be stopped. Second, participants need to 164 apply the rule associated with the cue (vertical bar = antisaccade) to select the 165 corresponding action (a saccade in the direction opposite to the cue). These steps 166 allow for different types of error: either a reflexive prosaccade is not stopped (an 167 inhibition failure), or the wrong action is selected (a choice error). 168
In the case of correct prosaccades, a similar process takes place with an important 169 twist: inhibition failures are correct responses on prosaccade trials. However, 170 when reflexive saccades are stopped, subjects still need to select the correct 171 action associated with the cue (horizontal bar = prosaccade). When the wrong 172 action is selected, an (error) antisaccade is generated. 173
To quantify the effects of levodopa and galantamine on inhibitory control and 174 action selection, it is therefore necessary to disentangle when subjects fail to 175 inhibit reflexive prosaccades (inhibition failures), and when they fail to select the 176 correct action (choice errors). Because none of these can be directly measured, 177
we fitted the SERIA model to individual RT distributions
(Fig. 1B-C and Supp 3). 178
In brief, SERIA asserts that saccades are the result of the competition between 179 four race-to-threshold processes or units (see Fig. 1C The second main goal of this study was to test whether it is possible to determine 215 if a given participant received levodopa or galantamine based on computational 216 parameters derived from our model. To this end, a supervised classification 217 algorithm was trained on individual model-based features computed from 218 parameter estimates, with the aim to predict the drug administered on a subject-219 by-subject basis. More concretely, the features used to train the classifier were 220 subject-specific differences in parameter estimates between the drug and placebo 221
conditions. This "generative embedding" (51) strategy is a way to enhance 222 (un)supervised learning by using posterior estimates from a generative model, 223
instead of raw data, as a denoised and low-dimensional feature space. 224
Classification was performed using gradient boosting (52) implemented in 225 xgboost (53). The details of the classification strategy are explained in Supp. 4. 226 227
Results
228
For example, RT is thought to represent attentional shifting velocity (54) and 238 saccadic processing velocity (58). An extended overview of behavioral effects is 239 presented in Supp. 6 and 7. 240
Error rate 241
The mean ER on pro-and antisaccade trials is displayed in Fig. 2 top row. High 242 congruent trial type probability was associated with fewer errors on pro-( < 243 10 56 ) and antisaccade trials ( < 10 56 ). For example, participants made fewer 244 prosaccade errors (antisaccades) when prosaccade trials were most common 245 (PP80 block), compared to other blocks (PP20 and PP50). 246
Error rate -drug effects 247
Levodopa reduced the ER on prosaccade trials ( = 0.010). This effect was dose 248 dependent ( = 0.004). On antisaccade trials, we found no significant main 249 effect of DRUG in Exp. 1 or 2, but there was a significant interaction between 250 DRUG and DOSE in Exp. 2 ( < 10 56 ). Galantamine increased antisaccade ER at 251 high doses, while it reduced it at more moderate levels. 252
Reaction time 253
RT on correct trials were analyzed similarly to ER (Fig. 2 bottom row) . Higher 254 congruent trial type probability led to lower RT in both pro-( < 10 56 ) and 255 antisaccade trials ( < 10 56 ). 256
Reaction times -drug effects 257
Levodopa increased the latency of antisaccades compared to galantamine (Fig.  258 2H; < 10 57 ). When the two experiments were analyzed independently, we 259 found that galantamine decreased antisaccade RT ( < 10 57 ). No other effect 260 was significant. 261 
Modeling 262
The classical behavioral analysis revealed three drug related effects: (i) Levodopa 263 reduced the ER on prosaccade trials, (ii) galantamine reduced antisaccade 264 latency and (iii) increased the antisaccade ER in a dose dependent fashion. In 265 order to relate the behavioral findings to inhibitory control or action selection, 266 we applied computational modeling to our behavioral data. Our main goal was 267 to determine whether levodopa and galantamine affected (i) the hit time of the 268 inhibitory and late units, (ii) the probability of inhibition failures (inhibitory 269 control), and (iii) the probability of choice errors (action selection). Drug effects 270 on the hit times of the inhibitory or late units would demonstrate effects specific 271 to either inhibitory control or action selection. 272
Threshold hit times 273
The hit times of the inhibitory, and late pro-and antisaccade units were analyzed 274 as in the previous section. Contrary to raw RT, these can be imputed directly to 275 the inhibition of reflexive prosaccades or to voluntary actions. For the late units, 276
we report the expected hit times on correct trials. In the case of the inhibitory 277 unit, pro-and antisaccade trials were analyzed together. 278
In agreement with (39; 42), we found that the hit time of the inhibitory unit 279 increased with the frequency of prosaccade trials ( < 10 57 ), indicating reduced 280 inhibition when prosaccade trials were more common. 281
Threshold hit times -Drug effects 282
Levodopa increased the latency of voluntary actions ( Fig. 3A-B 
Corrective antisaccades 295
In (39; 42), we showed that corrective antisaccades that follow errors on 296 antisaccade trials are distributed like late responses up to a fixed delay. 297
Consequently, SERIA predicts that corrective antisaccades should display the 298 same drug effects as antisaccades, i.e., slower corrective antisaccades in the 299 levodopa condition and faster antisaccades in the galantamine condition. 300
We analyzed 5696 corrective saccades in Exp. 1 and 4996 in Exp. 2. Because the 301 frequency of corrective antisaccades varied widely over subjects and conditions, 302
we accounted for the inhomogeneous number of trials by analyzing trial-by-trial 303 RT as opposed to mean RT, using a strategy similar to (55). 304
Supporting our hypothesis (Fig. 3C) , levodopa increased the RT of corrective 305 antisaccades (Δ = 8 ; ; = 1.11; < 10 57 ), whereas galantamine had the 306 opposite effect (Δ = −10 ; ; = 1.52; < 10 57 ). 307
Inhibition failures and choice errors 308
We proceeded to investigate the probability of choice errors and inhibition 309 failures. Choice errors occur when the incongruent voluntary action hits 310 threshold before the congruent action. In other words, choice errors happen 311 when the wrong voluntary action is selected. An inhibition failure occurs when 312 the early unit hits threshold before all other units. 313
Choice error rate was anticorrelated with congruent trial type probability (late 314 pro: < 10 56 ; anti: < 10 56 ). Thus, the correct voluntary action was selected 315 most often when the probability of the corresponding trial type was the highest. 316
The probability of an inhibition failure was positively correlated with prosaccade 317 trial probability ( < 10 56 ). This indicates that inhibitory control was released as 318 prosaccade trials became more common. 319
Inhibition failures and choice errors -drug effects 320
Levodopa significantly reduced the probability of choice errors on pro-and 321 antisaccade trials ( Fig. 3D-E; pro.: Δ = 1.5%; < 10 57 ; anti.: Δ = 2.1%; < 322 10 56 ). By contrast, levodopa increased the probability of inhibition failures, 323 although this effect was not significant (Δ = 1.6%, = 0.082). Therefore, 324 levodopa mainly improved the ability to select correct voluntary actions, at the 325 cost of higher RT. 326
Galantamine decreased the probability of choice errors on antisaccade trials ( < 327 10 56 ). On prosaccade trials, galantamine did not have a significant effect ( = 328 0.095). There was no significant main effect of galantamine on the number of 329 inhibition failures ( = 0.590). 330
Dose dependent effects 331
In addition to the main effects of galantamine and levodopa, we investigated any 332 dose dependent effect. At low doses, levodopa reduced the probability of choice 333 errors on prosaccade trials. This effect was reversed at higher doses ( Fig. 4A; <  334 10 56 ). While the main effect of DRUG was not significant in Exp. 2, galantamine 335 had a highly significant dose dependent effect on the latency of the inhibitory 336 unit ( Fig. 4B ; < 10 57 ). This was reflected by a linear effect on inhibition failure 337 probability ( < 10 57 ). At low doses, galantamine reduced the hit time of the 338 inhibitory unit and the inhibition failure probability, and this effect was reversed 339 at higher doses. 340 . At a high dose, levodopa increased the number of errors, whereas at more moderate levels, it had the opposite effect. B. Difference (galantamine -placebo) in the percentage of inhibition failures averaged across conditions. Galantamine increased the number of inhibition failures as a function of dose ( < 10 57 ). C. Difference (galantamine -placebo) in the RT of the inhibitory unit averaged across conditions. Galantamine increased the latency of the inhibitory unit as a function of dose ( < 10 57 ).
Classification of drug effects 341
Finally, we tested whether the effects of levodopa and galantamine on 342 computational parameters can be used to predict which of the two drugs was 343 administered (Fig. 5) . Leave-one-out cross-validation resulted in 70% predictive 344 accuracy (95% CI [61%, 79%]). A permutation test, in which the levodopa and 345 galantamine labels were randomly swapped, showed that the predictive accuracy 346 was highly significant (p<0.001). A second permutation test (in which the drug 347 and placebo labels were randomly swapped) yielded a similar result (p=0.001; 348 Fig. 5 ). Because drug/placebo labels (but not experiment labels) were permuted, 349 this second test rules out that the accuracy of the classifier depended on a 350 difference between experiments not related to the drug administered. 351 Step 1. Data from N=90 subjects were split into test and training sets leaving one subject out at each iteration.
Step 2. To generate training features, the SERIA model was fitted to data from N-1 subjects.
Step 3. A gradient boosting classifier was trained on the SERIA parameter estimates using the drug labels from the previous step.
Step 4. Test features were generated by fitting SERIA to data from all N subjects.
Step 5. Weights from classifiers trained on N-1 subjects were used to predict the drug label of the left-out subjects. This resulted in a predictive accuracy of 70% (95% CI Split data
Step 1
Step 2
Step 3
Step 4
Step 5 Galantamine affected both action selection and inhibitory control. Specifically, 374 voluntary actions were facilitated by galantamine: RT were lower compared to 375 placebo. Galantamine also improved the inhibition of reflexive actions at lower 376 doses but had the opposite effect at higher levels. Thus, contrary to commonly 377 held hypotheses (9; 10), dopaminergic neuromodulation affected action 378 selection rather than inhibitory control. However, cholinergic neuromodulation 379 strongly affected inhibitory control. Notably, these effects were specific enough 380 to allow for identifying the administered drug on a subject-by-subject basis with 381 reasonable accuracy. This suggests the potential for a future translation of our 382 method into clinical applications. 383
In the following, we discuss our findings in relation to levodopa, galantamine, 384 and possible clinical applications. 385
Effects of levodopa 386
Although levodopa has been used widely in translational research (60), it has not 387 been studied systematically in the antisaccade task (but see (61; 62) 
Effects of galantamine 418
While the effects of nicotine on antisaccades have been investigated previously 419 (25-34; 67; 68), to our knowledge, this is the first antisaccade study applying a 420 more general pro-cholinergic drug (as an AChE inhibitor, galantamine raises ACh 421 levels in general). Our findings replicate previous studies in which nicotine was 422 found to reduce antisaccade RT (25; 27; 28; 30; 33). 423
In addition to the effect on voluntary responses, galantamine also affected 424 inhibition failure probability in a dose-dependent fashion. At a high dose, 425 galantamine had a deleterious effect, whereas at more moderate levels, it 426 improved performance. A comparable effect was reported previously (69), and it 427 agrees with dose-dependent effects observed in vitro (48) and in vivo in rodents 428 (70). In patients with schizophrenia, galantamine at high doses (32mg/day) 429 impairs inhibitory control (71). 430
Although deficits on the antisaccade task have been related to DA dysregulation 431 in the BG, the BG are also strongly modulated by cholinergic processes, due to 432 local cholinergic interneurons and afferent projections from cholinergic nuclei 433 (76). Our results suggest that cholinergic neuromodulation is also relevant to 434 explain deficits in inhibitory control. 
